Multinational Suitors Queue Up As India's Paras Pharma Valuation Shoots Above $1 Billion
This article was originally published in The Pink Sheet Daily
Executive Summary
Among expected MNC bidders in the equity holding are GlaxoSmithKline, which is likely represented by Merrill Lynch; and Sanofi-Aventis, which is said to have mandated London-headquartered Rothschild to assist with its bid. Novartis and Johnson & Johnson are also considered to be potential buyers.
You may also be interested in...
Sanofi-Aventis Will Enter U.S. OTC Market By Paying $1.9 Billion For Chattem
The deal, which is Sanofi's latest attempt to diversity in the face of a looming patent cliff, provides a platform for Rx-to-OTC switches.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
One Trial Plus Supportive Evidence Is Enough For Hospital-, Ventilator-Acquired Pneumonia Indication, Panel Says
Anti-Infective Drugs Advisory Committee members viewed one-trial as practical means of gaining efficacy data.